source
- AbbVie’s once-daily Parkinson’s pill receives FDA approvalAbbVie announced that the U.S. Food and Drug Administration has granted approval for its once‑daily oral therapy for Parkinson’s disease. The decision allows the product to be marketed in the Unite…
- GLP-1 drugs shift from obesity treatment to lifestyle products, prompting setbacks for Merck and DaiichiThe column notes that GLP-1 medicines, originally marketed to treat obesity as a medical condition, are now being promoted more as general lifestyle enhancers for appearance and wellbeing. Novo No…